1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

ECR Pharmaceuticals

Anonymous board for ECR Pharmaceuticals

Sort By:
Title
Replies Views
Last Message ↓
  1. anonymous
    Replies:
    3
    Views:
    1,224
  2. anonymous
    Replies:
    9
    Views:
    2,493
  3. anonymous
    Replies:
    1
    Views:
    972
  4. anonymous
    Replies:
    0
    Views:
    785
  5. anonymous
    Replies:
    2
    Views:
    1,564
  6. anonymous
    Replies:
    0
    Views:
    1,506
  7. anonymous
    Replies:
    0
    Views:
    1,201
  8. anonymous
    Replies:
    1
    Views:
    1,674
  9. anonymous
    Replies:
    0
    Views:
    1,542
  10. anonymous
    Replies:
    0
    Views:
    1,461
  11. Anonymous
    Replies:
    1
    Views:
    2,180
  12. Anonymous
    Replies:
    2
    Views:
    2,239
  13. Anonymous
    Replies:
    6
    Views:
    2,900
  14. Anonymous
    Replies:
    1
    Views:
    3,331
  15. Anonymous
    Replies:
    2
    Views:
    2,824
  16. Anonymous
    Replies:
    10
    Views:
    4,612
  17. Anonymous
    Replies:
    7
    Views:
    4,953
  18. Anonymous
    Replies:
    99
    Views:
    22,934
  19. Anonymous
    Replies:
    13
    Views:
    4,968
  20. Anonymous
    Replies:
    7
    Views:
    4,533

Thread Display Options

Loading...